Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
Identifieur interne : 002B78 ( Istex/Curation ); précédent : 002B77; suivant : 002B79Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
Auteurs : Brotchie [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-11.
English descriptors
- KwdEn :
Abstract
Dyskinesias following long‐term dopamine replacement therapy are a major limitation of current treatments for Parkinson's disease. Recently, attention has been focused on the concept of using non‐dopaminergic adjuncts to currently available therapies in an attempt to reduce the problem of dyskinesia. Thus, an enhanced understanding of the neural mechanisms underlying dyskinetic symptoms has led to the realization that it might be possible to manipulate non‐dopaminergic systems and reduce dyskinesia without compromising the antiparkinsonian efficacy of drugs such as L‐dopa. This article discusses how non‐dopaminergic manipulations could reverse the abnormalities in basal ganglia circuitry responsible for generating dyskinesia. It is proposed that potential anti‐dyskinetic drugs might include glutamate (NMDA) receptor antagonists, opioid receptor antagonists, cannabinoid receptor agonists or antagonists, α2 adrenergic receptor antagonists, and 5‐HT‐enhancing agents.
Url:
DOI: 10.1002/mds.870130603
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B78
Links to Exploration step
ISTEX:79015B5ACD997052F7DF3A0E2757D2DF2429325BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</title><author><name sortKey="Brotchie" sort="Brotchie" uniqKey="Brotchie" last="Brotchie">Brotchie</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:79015B5ACD997052F7DF3A0E2757D2DF2429325B</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130603</idno><idno type="url">https://api.istex.fr/document/79015B5ACD997052F7DF3A0E2757D2DF2429325B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B78</idno><idno type="wicri:Area/Istex/Curation">002B78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease</title><author><name sortKey="Brotchie" sort="Brotchie" uniqKey="Brotchie" last="Brotchie">Brotchie</name><affiliation wicri:level="1"><mods:affiliation>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-11">1998-11</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="871">871</biblScope><biblScope unit="page" to="876">876</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">79015B5ACD997052F7DF3A0E2757D2DF2429325B</idno><idno type="DOI">10.1002/mds.870130603</idno><idno type="ArticleID">MDS870130603</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term><term>MPTP</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias following long‐term dopamine replacement therapy are a major limitation of current treatments for Parkinson's disease. Recently, attention has been focused on the concept of using non‐dopaminergic adjuncts to currently available therapies in an attempt to reduce the problem of dyskinesia. Thus, an enhanced understanding of the neural mechanisms underlying dyskinetic symptoms has led to the realization that it might be possible to manipulate non‐dopaminergic systems and reduce dyskinesia without compromising the antiparkinsonian efficacy of drugs such as L‐dopa. This article discusses how non‐dopaminergic manipulations could reverse the abnormalities in basal ganglia circuitry responsible for generating dyskinesia. It is proposed that potential anti‐dyskinetic drugs might include glutamate (NMDA) receptor antagonists, opioid receptor antagonists, cannabinoid receptor agonists or antagonists, α2 adrenergic receptor antagonists, and 5‐HT‐enhancing agents.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002B78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:79015B5ACD997052F7DF3A0E2757D2DF2429325B
|texte= Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |